Show simple item record

dc.contributor.authorStewart, Granten
dc.contributor.authorPowles, Ten
dc.contributor.authorVan Neste, Cen
dc.contributor.authorMeynert, Aen
dc.contributor.authorO'Mahony, Fen
dc.contributor.authorLaird, Aen
dc.contributor.authorDeforce, Den
dc.contributor.authorVan Nieuwerburgh, Fen
dc.contributor.authorTrooskens, Gen
dc.contributor.authorVan Criekinge, Wen
dc.contributor.authorDe Meyer, Ten
dc.contributor.authorHarrison, DJen
dc.date.accessioned2016-03-17T09:17:03Z
dc.date.available2016-03-17T09:17:03Z
dc.date.issued2016-05-03en
dc.identifier.citationStewart et al. Oncotarget (2016)en
dc.identifier.issn1949-2553
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/254534
dc.description.abstractBackground: Genetic intratumoral heterogeneity (ITH) hinders biomarker development in metastatic clear cell renal cancer (mccRCC). Epigenetic relative to genetic ITH or the presence of consistent epigenetic changes following targeted therapy in mccRCC have not been evaluated. The aim of this study was to determine methylome/genetic ITH and to evaluate specific epigenetic and genetic changes associated with sunitinib therapy. Patients and methods: Multi-region DNA sampling performed on sequential frozen pairs of primary tumor tissue from 14 metastatic ccRCC patients, in the Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients with Metastatic Renal Cancer: a Pilot Phase II Study (SuMR; ClinicalTrials.gov identifier: NCT01024205), at presentation (biopsy) and after 3-cycles of 50mg sunitinib (nephrectomy). Untreated biopsy and nephrectomy samples before and after renal artery ligation were controls. Ion Proton sequencing of 48 key ccRCC genes, and MethylCap-seq DNA methylation analysis was performed, data was analysed using the statistical computing environment R. Results: Unsupervised hierarchical clustering revealed complete methylome clustering of biopsy and three nephrectomy samples for each patient (14/14 patients). For mutational status, untreated biopsy and all treated nephrectomy samples clustered together in 8/13 (61.5%) patients. The only methylation target significantly altered following sunitinib therapy was VHL promoter region 7896829 which was hypermethylated with treatment (FDR=0.077, P<0.001) and consistent for all patients (pre-treatment 50% patients had VHL mutations, 14% patients VHL hypermethylation). Renal artery ligation did not affect this result. No significant differences in driver or private mutation count was found with sunitinib treatment. Conclusions: Demonstration of relative methylome homogeneity and consistent VHL hypermethylation, after sunitinib, may overcome the hurdle of ITH present at other molecular levels for biomarker research.
dc.description.sponsorshipThis work was supported by: Chief Scientist Office, Scotland (grant number ETM37 to GDS and DJH); Cancer Research UK (Experimental Cancer Medicine Centre) (to TP, London and DJH, Edinburgh), Medical Research Council (to AL, DJH), Royal College of Surgeons of Edinburgh (to AL), Melville Trust (to AL), Renal Cancer Research Fund (to GDS), Kidney Cancer Scotland (to GDS), the Special Research Fund of Ghent University (grant number 01MR0410 to TDM, GT, WVC, CVN, FVN and DD) and an educational grant from Pfizer (to TP).
dc.languageengen
dc.language.isoenen
dc.publisherImpact Journals
dc.rightsAttribution 4.0 International
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectVHLen
dc.subjectheterogeneityen
dc.subjectmethylationen
dc.subjectmutationsen
dc.subjectrenal canceren
dc.titleDynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.en
dc.typeArticle
prism.endingPage25250
prism.issueIdentifier18en
prism.publicationDate2016en
prism.publicationNameOncotargeten
prism.startingPage25241
prism.volume7en
dc.rioxxterms.funderCRUK
dc.rioxxterms.funderMRC
dcterms.dateAccepted2016-03-10en
rioxxterms.versionofrecord10.18632/oncotarget.8308en
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2016-05-03en
dc.contributor.orcidStewart, Grant [0000-0003-3188-9140]
dc.identifier.eissn1949-2553
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2016-03-23en
cam.orpheus.successThu Jan 30 12:54:50 GMT 2020 - The item has an open VoR version.*
rioxxterms.freetoread.startdate2100-01-01


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International